Tiankang Bio's controlling subsidiary, Tiankang Pharmaceutical, received a decision from the Beijing Stock Exchange to terminate the review of its public offering. This follows the withdrawal of the IPO application due to a significant decline in performance. The termination is not expected to materially impact Tiankang Bio's operations or financial status.
Summary generated by AI · Always verify with source document
Tiankang Bio Co., Ltd.
Announcement on Receiving the Decision from Beijing Stock Exchange to Terminate the Review of Tiankang Pharmaceutical Co., Ltd.'s Public Offering of Shares on the Beijing Stock Exchange
The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and have no false records, misleading statements, or major omissions.
I. Basic Information
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.